BioCentury
ARTICLE | Clinical News

BHR-100 progesterone regulatory update

December 14, 2009 8:00 AM UTC

FDA granted Orphan Drug designation for BHR-100 to treat moderate to severe traumatic brain injury (TBI). BHR Pharma LLC, a subsidiary of Besins, plans to begin a Phase III trial of the intravenous pr...